Minimally Invasive Interventions Will Capture New Global Markets

Key Takeaways

• Expanding global demand and healthcare trends strongly favor Creo's advanced energy portfolio, driving sustained growth in market share, revenue, and profit margins.
  
• Strategic alliances, new product launches, and cost-saving operational changes are set to accelerate international expansion, boost utilization, and improve overall profitability.
  
• Unpredictable revenues, persistent cost pressures, missed forecasts, and heightened competitive and macroeconomic risks threaten profitability and challenge the company's ability to meet long-term targets.

Catalysts

Through its subsidiaries, engages in the research, development, manufacture, and sale of medical devices and instruments in the United Kingdom.

• The global demand for minimally invasive interventions is set to increase due to an aging population and rising chronic disease prevalence, positioning Creo's expanding advanced energy portfolio to capture long-term structural growth in patient volumes-positively impacting revenue growth and market share.
  
• Healthcare systems' ongoing shift toward value-based, outpatient care and cost reduction strongly favors Creo's clinically validated device suite, which reduces complication and hospital stays-supporting both higher utilization and an expansion of gross and net margins as adoption accelerates.
  
• The strategic alliance with Micro-Tech opens further growth in large and underpenetrated international markets such as China, leveraging Micro-Tech's distribution and co-development strengths; this catalyst is likely to materially accelerate revenue growth and drive incremental EBITDA from both royalties and equity interests.
  
• The ramp-up of in-house product launches and indications (Speedboat, SpydrBlade, MicroBlate) alongside improved reimbursement in the US and Europe sets up sustained multi-year growth in both average customer utilization and account penetration, enhancing top-line growth and operational leverage.
  
• Streamlined operations and a shift to outsourced, lower-cost manufacturing, combined with significant administrative expense reductions already underway, are expected to drive margin improvement, speeding the path to profitability and cash generation.

Creo Medical Group Future Earnings and Revenue Growth

Assumptions

• Analysts are assuming Creo Medical Group's revenue will grow by 63.8% annually over the next 3 years.
• Analysts are not forecasting that Creo Medical Group will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Creo Medical Group's profit margin will increase from -695.0% to the average GB Medical Equipment industry of 10.2% in 3 years.
• If Creo Medical Group's profit margin were to converge on the industry average, you could expect earnings to reach £1.8 million (and earnings per share of £0.0) by about July 2028, up from £-27.8 million today.
• In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 243.4x on those 2028 earnings, up from -2.0x today. This future PE is greater than the current PE for the GB Medical Equipment industry at 43.1x.
• Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.61%, as per the Simply Wall St company report.

Creo Medical Group Future Earnings Per Share Growth

Risks

• Despite increased revenue in the core product line, overall group sales were flat year-on-year due to discontinued operations and reliance on milestone payments from speculative licensing deals in prior periods-raising concerns about the stability and predictability of future revenue growth.
  
• The company has repeatedly missed past sales forecasts, attributed to overestimation of licensing revenues and slower-than-expected commercialization, which indicates elevated execution risk and uncertainty in achieving ambitious long-term financial targets (impact: revenue, earnings).
  
• Persistent high admin and development expenses, only recently addressed through cost-cutting measures, mean any slowdown in revenue growth or market adoption could quickly erode margins and delay the timeline to profitability (impact: net margins, cash flow).
  
• Near-term revenue projections exclude potential new licensing or robotic partnership deals, while a significant portion of future profitability is tied to dividend streams from the partially divested Creo Medical Europe-making core business performance and new product adoption even more critical (impact: earnings consistency, revenue risk).
  
• Macroeconomic uncertainty, potential tariff risks for US market entry, reimbursement delays, and competitive dynamics (especially from larger, better-capitalized multinationals or rapid technological shifts) pose ongoing threats to Creo's market share, product pricing, and margin improvements (impact: revenue, margins, competitive positioning).

Valuation

• The analysts have a consensus price target of £0.707 for Creo Medical Group based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of £1.02, and the most bearish reporting a price target of just £0.4.
• In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be £17.6 million, earnings will come to £1.8 million, and it would be trading on a PE ratio of 243.4x, assuming you use a discount rate of 7.6%.
• Given the current share price of £0.14, the analyst price target of £0.71 is 80.2% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.